Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.
Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
